Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care

NCT02187367 is registered in ClinicalTrials.gov with Bioven Europe as lead sponsor.

NCT NCT02187367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02187367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care
Lead sponsor
Bioven Europe
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2015
Completion date
September 6, 2019
Enrollment
106 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung